Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Current Deferred Revenue (2016 - 2023)

Fortress Biotech (FBIO) has 6 years of Current Deferred Revenue data on record, last reported at $547000.0 in Q1 2023.

  • For Q1 2023, Current Deferred Revenue fell 73.11% year-over-year to $547000.0; the TTM value through Mar 2023 reached $547000.0, down 73.11%, while the annual FY2022 figure was $728000.0, 72.12% down from the prior year.
  • Current Deferred Revenue reached $547000.0 in Q1 2023 per FBIO's latest filing, down from $728000.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $7.2 million in Q1 2021 and bottomed at $547000.0 in Q1 2023.
  • Average Current Deferred Revenue over 3 years is $2.6 million, with a median of $2.0 million recorded in 2022.
  • Peak YoY movement for Current Deferred Revenue: crashed 67.41% in 2022, then tumbled 73.11% in 2023.
  • A 3-year view of Current Deferred Revenue shows it stood at $2.6 million in 2021, then tumbled by 72.12% to $728000.0 in 2022, then dropped by 24.86% to $547000.0 in 2023.
  • Per Business Quant database, its latest 3 readings for Current Deferred Revenue were $547000.0 in Q1 2023, $728000.0 in Q4 2022, and $1.1 million in Q3 2022.